ESR1 and breast carcinoma: Indeed, this was shown when Torres-Roca et al. presented the follow-up study of RSI in estrogen receptor positive (ER+) and estrogen receptor negative (ER-) breast cancer, and only could validate previous findings in ER- tumors [16].